Vernalis hands over first milestone to Tris 'on proof-of-concept'
This article was originally published in Scrip
Executive Summary
Vernalis of the UK has made the first milestone payment under its US prescription cough cold alliance with Tris Pharma after the "achievement of proof-of-concept" for the first collaboration programme, CCP-01. Under the collaboration with Tris, proof-of-concept required the successful completion of several activities, including a successful human pilot comparative study against an immediate release reference product.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.